Pharmaceutical approval update

P T. 2013 Nov;38(11):705-7.

Abstract

Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma.